Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.10
- Piotroski Score 1.00
- Grade Buy
- Symbol (LIFE)
- Company aTyr Pharma, Inc.
- Price $1.90
- Changes Percentage (2.7%)
- Change $0.05
- Day Low $1.82
- Day High $1.95
- Year High $2.45
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 08/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $11.00
- High Stock Price Target $11.00
- Low Stock Price Target $11.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.88
- Trailing P/E Ratio -2.16
- Forward P/E Ratio -2.16
- P/E Growth -2.16
- Net Income $-50,389,000
Income Statement
Quarterly
Annual
Latest News of LIFE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Integra Lifesciences Holdings Corp (IART) Q3 2024 Earnings Call Highlights: Navigating ...
Expect mid-single-digit organic growth in 2025 despite quality holds in Q4. No significant hurricane impacts on procedures or IV shortages. $10 million impact from shipping holds in Q4. Gross margin h...
By Yahoo! Finance | 14 hours ago -
Alex Merkviladze scores 22, leads Loyola Marymount over Life Pacific 99-56
Loyola Marymount dominated Life Pacific with Alex Merkviladze scoring 22 points and 9 rebounds. Myron Amey Jr. added 20 points with 4 steals. Caleb Stone-Carrawell contributed 16 points....
By AP NEWS | 14 hours ago -
Real Housewives of New Jersey star Dolores Catania Calls The Traitors Season 3 'The Best Experience of My Life'
Catania shared her excitement about her experience on the hit reality series The Traitors, set to debut on Jan. 9, 2025....
By PEOPLE.com | 15 hours ago
